Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2013

Feb 14, 2013

30291_dirs_2013-02-14_699b6016-0082-4d3d-bc7b-0e9b8bedf667.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2013-02-12

Reporting Person: SCANGOS GEORGE A (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-02-13 Common Stock S 1598 $163.39 Disposed 55303 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-02-12 Restricted Stock Unit $0 A 36758 Acquired 2017-02-12 Common Stock (36758) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5378 Indirect
Common Stock 5378 Indirect

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).